Antipsychotic medication in adolescents suffering from Schizophrenia: A meta-analysis of randomized controlled trials

Psychopharmacology Bulletin

Volumn 43, Issue 2, 2010, Pages 45-66

  Ardizzone, Ignazio ^a   Nardecchia, Francesca ^a   Marconi, Arianna ^a   Carratelli, Teresa I ^a   Ferrara, Mauro ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Adolescents; Adverse effects; Antipsychotics; Early onset; Efficacy; Extrapyramidal side effects; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; OLANZAPINE; RISPERIDONE;

ADOLESCENT HEALTH; AKATHISIA; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG APPROVAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LOW DRUG DOSE; META ANALYSIS; PARKINSONISM; POSITIVE AND NEGATIVE SYNDROME SCALE; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT OUTCOME; TREMOR; WEIGHT GAIN;

ADOLESCENT; AGE FACTORS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DOUBLE-BLIND METHOD; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MALE; MULTICENTER STUDIES AS TOPIC; PATIENT SELECTION; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 79951986488     PISSN: 00485764     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (80)

1. Cosway R, Byrne M, Clafferty R, Hodges A, Grant E, Abukmeil SS, Lawrie SM, Miller P, Johnstone EC. Neuropsychological change in young people at high risk for schizophrenia: results from the first two neuropsychological assessments of the Edinburgh High Risk Study. Psychol Med. 2000;30:1111-21.
2. Remschmidt H. Schizophrenia in Children and Adolescents (with Ian M. Goodyer). Cambridge: Cambridge University press, 2001.
3. Leask SJ, Done DJ, Crow TJ. Adult psychosis, common childhood infections and neurological soft signs in a national birth cohort. Br J Psychiatry. 2002 Nov; 181:387-92. (Pubitemid 35333105)
4. American Psychiatric Association. Diagnostic and statistical manual of mental disorders third edition (DSM-III). 1980, Washington, DC.
5. Remschmidt H. Early-onset schizophrenia as a progressive-deteriorating developmental disorder: evidence from child psychiatry J Neural Transm. 2002;109(1):101-17. (Pubitemid 34146593)
6. Werry JS. Child psychiatric disorders: are they classifiable? Br J Psychiatry. 1992;161:472-80.
7. Russell AT. The clinical presentation of childhood-onset schizophrenia. Schizophr Bull. 1994;20:631-46. (Pubitemid 24373735)
8. Bailly D, de Chouly de Lenclave MB. A rare and not very studied disorder: childhood-onset schizophrenia. A case report. Encephale. 2004;30:540-7.
9. Ballageer T, Malla A, Manchanda R, Takhar J, Haricharan R. Is adolescent-onset first-episode psychosis different from adult onset? J Am Acad Child Adolesc Psychiatry. 2005;44:782-9. (Pubitemid 41026282)
10. Harris MG, Henry LP, Harrigan SM, Purcell R, Schwartz OS, Farrelly SE, Prosser AL, Jackson HJ, McGorry PD. The relationship between duration of untreated psychosis and outcome: an eight-year prospective study. Schizophr Res. 2005;79:85-93. (Pubitemid 41362596)
11. Armenteros JL, Davies M. Antipsychotics in early onset Schizophrenia. Systematic review and metaanalysis. Eur Child Adolescent Psycghiatry. 2006;15:141-148.
12. Jensen PS, Buitelaar J, Binder C, Haas M. Management of psychiatric disorders in children and adolescents with atypical antipsychotics. A systematic review of published clinical trials. Eur Child Adolesc Psychiatry. 2007;16, 104-120. (Pubitemid 46643895)
13. Greene RW, Biederman J, Zerwas S, Monuteaux MC, Goring JC, Faraone SV. Psychiatric comorbidity, family, dysfunction, and social impairment in referred youth with oppositional defiant disorder. Am J Psychiatry. 2002;159:1214-1224. (Pubitemid 34743264)
14. Remschmidt H, Schulz E, Martin PM. An open trial of clozapine in thirty-six adolecsents with schizophrenia. J Child Adolesc Psychopharmacol. 1994;4:31-41. (Pubitemid 24170577)
15. Scott S, Knapp M, Henderson J, Maughan B. Financial cost of social exclusion: follow up study of antisocial children into adulthood. BMJ. 2001;323:191-193.
16. Fitzgerald M. Unlicensed and off label drug use for children with child psychiatric problems. Ir Med J. 1999;92:284.
17. Pandolfini C, Impicciatore P, Provasi D, Rocchi F, Campi R, Bonati M, Italian Paediatric Off-label Collaborative Group. Off-label use of drugs in Italy: a prospective, observational and multicentre study. Acta Paediatr. 2002;91:339-47. (Pubitemid 34270876)
18. Olfson M, Blanco C, Liu L, Moreno C, Laje G. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry. 2006;63:679-85. (Pubitemid 43848299)
19. Bazzano AT, Mangione-Smith R, Schonlau M, Suttorp MJ, Brook RH. Off-label prescribing to children in the United States outpatient setting. Acad Pediatr. 2009;9:81-8.
20. Kölch M, Allroggen M, Fegert JM. Off-label use in child and adolescent psychiatry. An ongoing ethical, medical and legal problem. Nervenarzt. 2009;80:789-96.
21. Jerrell JM, Hwang TL, Livingston TS. Neurological adverse events associated with antipsychotic treatment in children and adolescents. J Child Neurol. 2008 Dec; 23(12):1392-9.
22. Ratzoni G, Gothelf D, Brand-Gothelf A, Reidman J, Kikinzon L, Gal G, Phillip M, Apter A, Weizman R. Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J Am Acad Child Adolesc Psychiatry. 2002;41:337-43. (Pubitemid 38338156)
23. Correll CU. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry. 2008;69 Suppl 4:26-36.
24. Benes FM, Taylor JB, Cunningham MC. Convergence and plasticity of monoaminergic systems in the medial prefrontal cortex during the postnatal period: implications for the development of psychopathology. Cereb Cortex. 2000;10:1014-1027.
25. Goldman-Rakic P, Leranth C, Williams S, Mons N, Geffard M. Dopamine synaptic complex with pyramidal neurons in primate cerebral cortex. Proc Natl Acad Sci USA. 1988;86:9015-9019.
26. Andersen S, Rutstein M, Benzo J, Hostetter J, Teicher MH. Sex differences in dopamine receptor overproduction and elimination. Neuroreport. 1997;8:1495-1498. (Pubitemid 27242562)
27. Teicher M, Barbar N, Gelbard H, Gallitano AL, Campbell A, Marsh E, Baldessarini RJ. Developmental differences in acute nigrostriatal and mesocorticolimbic system response to haloperidol. Neuropsychopharmacology. 1993;9:147-156. (Pubitemid 23275840)
28. Rosenberg D, Lewis D. Postnatal maturation of the dopaminergic innervation of monkey prefrontal and motor cortices: a tyrosine hydroxylase immunohistochemical analysis. J Comp Neurol. 1994;358:383-400.
29. Seeman P, Bzowej NH, Guan HC, Bergeron C, Reynolds GP, Bird ED, Riederer P, Jellinger K, Tourtellotte WW. Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. Neuropsychopharmacology. 1987;1:5-15. (Pubitemid 19125243)
30. Tarazi F, Baldessarini R. Regional localization of dopamine and ionotropic glutamate receptor substypes in striatolimbic brain regions. J Neurosci Res. 1999;55:401-410. (Pubitemid 29110548)
31. Feinberg I. Schizophrenia: caused by a fault in programmed synaptic elimination during adolescence? J Psychiatr Res. 1982-1983;17:319-334. (Pubitemid 14249821)
32. Claghorn JL. A double-blind comparison of haloperidol (haldol) and thioridazine (mellaril) in outpatient children. Current Therapeutic Research. 1972;14(12):785-9.
33. Fish B, Shapiro T, Campbell M. Long-term prognosis and the response of schizophrenic children to drug therapy: a controlled study of trifluoperazine. American Journal of Psychiatry. 1966;123(1):32-9.
34. Frazier JA, Gordon CT, McKenna K, Lenane MC, Jih D, Rapoport JL. An open trial of clozapine in 11 adolescents with childhood onset schizophrenia. Journal of the American Academy of Child and Adolescent Psychiatry. 1994;33(5):658-63. (Pubitemid 24167023)
35. Gram LF, Rafaelsen OJ. Lithium treatment of psychotic children and adolescents. A controlled clinical trial. Acta Psychiatrica Scandinavica. 1972;48(3):253-60.
36. Lewis PJ, James NM. Haloperidol and chlorpromazine - a doubleblind cross-over trial and clinical study in children and adolescents. Australian and New Zealand Journal of Psychiatry. 1973;7(1):59-65.
37. Liang L. A clinical trial of risperidone in treatment of childhood patients with first-episode schizophrenia. Journal of Clinical Psychological Medicine. 2003;13(1):20-1.
38. McGlashan TH, Zipursky RB, Perkins DO, Addington J, Woods SW, Miller TJ, Lindborg S, Marquez E, Hawkins K, Hoffman RE. Olanzapine versus placebo treatment of the schizophrenia prodrome: One year results. Schizophrenia Research. 2003;60:295.
39. Nagaraja J. Clinical use of haloperidol (serenace) in child psychiatry. Child Psychiatry Quarterly. 1977;10(4):14-20.
40. Sikich L, Hamer RM, Bashford RA, Sheitman BB, Lieberman JA. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomised, 8-week trial. Neuropyschopharmacology. 2004;29(1):133-45. (Pubitemid 38068023)
41. Inoue T, Domae M, Yamada K, Furukawa T. Effects of the novel antipsychotic agent 7-(4-[4-(2, 3-dichlorophenyl)-1-piperazinyl]butyloxy)-3, 4-dihydro-2 (1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. J Pharmacol Exp Ther. 1996;277:137-143.
42. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur europsychopharmacol. 2001;11(S3): S268.
43. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002;302:381-9. (Pubitemid 34680462)
44. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-23.
45. Beasley CM Jr, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology. 1996;124:159-67.
46. Sikich L, Hamer RM, Bashford RA, Sheitman BB, Lieberman JA. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology. 2004;29:133-45. (Pubitemid 38068023)
47. Mozes T, Ebert T, Michal SE, Spivak B, Weizman A. An open-label randomized comparison of olanzapine versus risperidone in the treatment of childhood-onset schizophrenia. J Child Adolesc Psychopharmacol. 2006;16:393-403. (Pubitemid 44681460)
48. Shaw P, Sporn A, Gogtay N, Overman GP, Greenstein D, Gochman P, Tossell JW, Lenane M, Rapoport JL. Childhood-onset schizophrenia: A double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry. 2006;63:721-30.
49. Sporn AL, Vermani A, Greenstein DK, Bobb AJ, Spencer EP, Clasen LS, Tossell JW, Stayer CC, Gochman PA, Lenane MC, Rapoport JL, Gogtay N. Clozapine treatment of childhood-onset schizophrenia: evaluation of effectiveness, adverse effects, and long-term outcome. J Am Acad Child Adolesc Psychiatry. 2007;46:1349-56. (Pubitemid 47462194)
50. Findling RL, Robb A, Nyilas M, Forbes RA, Jin N, Ivanova S, Marcus R, McQuade RD, Iwamoto T, Carson WH. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry. 2008;165:1432-41.
51. Jensen JB, Kumra S, Leitten W, Oberstar J, Anjum A, White T, Wozniak J, Lee SS, Schulz SC. A comparative pilot study of second-generation antipsychotics in children and adolescents with schizophrenia-spectrum disorders. J Child Adolesc Psychopharmacol. 2008;18:317-26.
52. Kumra S, Kranzler H, Gerbino-Rosen G, Kester HM, DeThomas C, Cullen K, Regan J, Kane JM. Clozapine versus "high-dose" olanzapine in refractory early-onset schizophrenia: an open-label extension study. J Child Adolesc Psychopharmacol. 2008;18:307-16.
53. Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, Ritz L, Ambler D, Puglia M, Maloney AE, Michael E, De Jong S, Slifka K, Noyes N, Hlastala S, Pierson L, McNamara NK, Delporto-Bedoya D, Anderson R, Hamer RM, Lieberman JA. Double-blind comparison of first-and secondgeneration antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry. 2008;165:1420-31.
54. Haas M, Eerdekens M, Kushner S, Singer J, Augustyns I, Quiroz J, Pandina G, Kusumakar V. Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind study. Br J Psychiatry. 2009;194:158-64.
55. Kryzhanovskaya L, Schulz SC, McDougle C, Frazier J, Dittmann R, Robertson-Plouch C, Bauer T, Xu W, Wang W, Carlson J, Tohen M. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2009;48:60-70.
56. Higgins JPT. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. In: Higgins JPT, Green S editor (s). The Cochrane Library Chichester, UK: John Wiley & Sons, Ltd., 2005.
57. Jadad A, Moore A, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials. 1996;17:1-12. (Pubitemid 26120810)
58. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273:408-12.
59. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009 Jan 3; 373(9657):31-41.
60. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Williamson D, Ryan N. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry. 1997 Jul; 36(7):980-8. (Pubitemid 27272932)
61. Borenstein M, Hedges L, Higgins J, Rothstein H. Comprehensive Metaanalysis Version 2. Englewood: Biostat; 2005.
62. Keepers GA, Clappison VJ, Casey DE. Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Arch Gen Psychiatry. 1983;40:1113-7. (Pubitemid 13006227)
63. Safer DJ, Zito JM, Gardner JF. Comparative prevalence of psychotropic medications among youths enrolled in the SCHIP and privately insured youths. Psychiatr Serv. 2004;55:1049-51. (Pubitemid 39209689)
64. Miller CH, Fleischhacker WW. Managing antipsychotic-induced acute and chronic akathisia. Drug Saf. 2000;22:73-81. (Pubitemid 30058028)
65. Pierre JM. Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management. Drug Saf. 2005;28:191-208. (Pubitemid 40364887)
66. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19 Suppl 1:1-93. (Pubitemid 40677047)
67. Allison DB, Mackell JA, McDonnell DD. The impact of weight gain on quality of life among persons with schizophrenia. Psychiatr Serv. 2003;54:565-7. (Pubitemid 36752990)
68. Advokat CD, Mayville EA, Matson JL. Side effect profiles of atypical antipsychotics, typical antipsychotics, or no psychotropic medications in persons with mental retardation. Res Dev Disabil. 2000;21:75-84. (Pubitemid 30133370)
69. Burns MJ. The pharmacology and toxicology of atypical antipsychotic agents. J Toxicol Clin Toxicol. 2001;39:1-14. (Pubitemid 32332271)
70. Tandon R, Rankapalli B. Comparative Efficacy and Safety of First - and Second-Generation Antipsychotics in the Treatment of Schizophrenia: Facts and Fiction. In: Gattaz WF and Busatto G. Advances in Schizophrenia Research. New York: Springer, 2009;389-401.
71. Kasper S, Müller-Spahn F. Review of quetiapine and its clinical applications in schizophrenia. Expert Opin Pharmacother. 2000;1:783-801.
72. Bryden KE, Carrey NJ, Kutcher SP. Update and recommendations for the use of antipsychotics in early-onset psychoses. J Child Adolesc Psychopharmacol. 2001;11:113-30. (Pubitemid 32588483)
73. Stigler KA, Potenza MN, McDougle CJ. Tolerability profile of atypical antipsychotics in children and adolescents. Paediatr Drugs. 2001;3:927-42. (Pubitemid 34074818)
74. Halbreich U, Palter S. Accelerated osteoporosis in psychiatric patients: possible pathophysiological processes. Schizophr Bull. 1996;22:447-54. (Pubitemid 26295347)
75. Young CM, Findling RL. Pharmacologic treatment of adolescent and child schizophrenia. Expert Rev Neurother. 2004;4:53-60. (Pubitemid 38082123)
76. Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry. 1997;154:457-65. (Pubitemid 27147597)
77. Merritt RJ. Obesity. Curr Probl Pediatr. 1982;12:1-58.
78. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults-The Evidence Report. National Institutes of Health. Obes Res. 1998;6 Suppl 2:51S-209S.
79. Laita P, Cifuentes A, Doll A, Llorente C, Cortés I, Parellada M, Moreno D, Ruiz-Sancho A, Graell M, Arango C. Antipsychotic-related abnormal involuntary movements and metabolic and endocrine side effects in children and adolescents. J Child Adolesc Psychopharmacol. 2007;17:487-502.
80. Arango C, Parellada M, Moreno DM. Clinical effectiveness of new generation antipsychotics in adolescent patients. Eur Neuropsychopharmacol. 2004;14 Suppl 4: S471-9 (Pubitemid 39574339)